What is already known about this subject?
Dapagliflozin is a potent sodium-glucose cotransporter type 2 inhibitor used for the treatment of type 2 diabetes mellitus (T2DM) worldwide, type 1 diabetes mellitus (T1DM) currently in Europe and Japan, and heart failure with reduced ejection fraction in USA and Europe.